Followers | 218 |
Posts | 38765 |
Boards Moderated | 0 |
Alias Born | 04/29/2008 |
Thursday, June 16, 2016 1:58:04 PM
If you look at the class action shareholder actions over the last few years regarding takeovers, they occur when the price rise isn't great enough.
When the price falls 40% and they sell a company with $40 million in cash for no money while giving the new company shareholders 80% of the new entity, I think you might find there are a few folks who feel there was some double dealing.
We'll see.
“No one in this world, so far as I know — and I have searched the records for years, and employed agents to help me — has ever lost money by underestimating the intelligence of the great masses of the plain people"
H.L. Mencken
Recent KALV News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year • Business Wire • 05/01/2024 10:30:00 AM
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors • Business Wire • 04/22/2024 10:30:00 AM
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/03/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas • Business Wire • 03/18/2024 10:30:00 AM
- KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat • Business Wire • 03/12/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:37:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/11/2024 08:26:19 PM
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update • Business Wire • 03/11/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:50:45 PM
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas • Business Wire • 03/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:38:33 AM
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer • Business Wire • 03/07/2024 11:30:00 AM
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/06/2024 11:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/04/2024 11:30:00 AM
- KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • Business Wire • 02/27/2024 11:30:00 AM
- KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • Business Wire • 02/26/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:15:27 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/22/2024 06:22:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:51:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:48:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:46:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:44:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:41:48 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM